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Obesity is a pervasive condition associated with increased risk of dementia, cognitive 
impairment, and cerebral atrophy in later life. Given that the pathophysiology underlying 
obesity’s impact on the central nervous system is poorly understood, the current study 
examined the association between body mass index (BMI) and five cerebral metabolites 
of neurobiological significance: N-acetyl-aspartate (NAA), a marker of neuronal 
viability; choline-containing compounds, free choline, phosphocholine and 
glycerophosphocholine (Cho), markers of membrane breakdown and turn over; creatine 
(Cr), a marker of energy metabolism; myo-inositol (mI), an organic osmolyte and 
substrate for the synthesis of the secondary messenger, inositol triphosphate; and 
glutamate (Glu), a marker of excitatory neurotransmission and synaptic integrity. Fifty-
five participants, aged 40-60 years, underwent neuropsychological testing, health screen 
and proton magnetic resonance spectroscopy (1H MRS) of the occipitoparietal grey 
matter. Concentrations of NAA, Cho, mI, and Glu were calculated as a ratio over Cr and 
examined in relation to BMI using multivariate multiple regression. Higher BMI was 
associated with elevations in mI/Cr (F(5,47)=3.583, p=0.008, ß=0.387, p=0.006), 




study found that higher BMI is related to increased concentrations of the organic 
osmoltye and glial marker myo-inositol, potentially implicating plasma hypertonicity and 
neuroinflammation as mechanisms underlying obesity-related brain dysfunction. With 
validation and absolute quantification, studies of neurometabolites may improve 
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1. BACKGROUND AND SIGNIFICANCE 
1.1 Overview 
Obesity has been declared a global pandemic based upon its striking prevalence 
across developed nations (1). Rates of overweight and obese status have increased 
dramatically over the past few decades with current estimates classifying over two-thirds 
of Americans as overweight or obese based upon body mass index (BMI) (BMI = weight 
(kilograms) / height2 (meters2)) (2). While obesity is most simplistically considered a 
condition of excess adipose tissue, its sequelae are diffuse, disrupting multiple 
physiological processes. Through both direct and indirect pathways, obesity damages the 
heart, liver, and pancreas, increasing susceptibility to a myriad of chronic diseases such 
as hypertension, diabetes, and cancer (3). Additionally, elevated BMI has been identified 
as a risk factor for cognitive decline (4-7), suggesting that the health consequences of 
obesity extend beyond the periphery. Cognitive impairment, even below threshold of 
dementia, is a significant determinant of long-term institutionalization and dependency in 
old age, placing strain on the economy and impairing overall quality of life of the aging 
population and their caregivers (8). Given the widespread prevalence of obesity and the 
progressive aging population, there is a pressing need to improve identification of the 
pathological mechanisms underlying obesity’s consequences on cognition. 
1.2 BMI and Cognition  
High BMI has been documented as both a risk for and a protective factor against 
cognitive impairment depending on the point of examination. High BMI in old age is 




vulnerability of future decline (9). In elderly adults, involuntary weight loss precedes the 
onset of dementia and accelerates with proximity to diagnosis (11). Additionally, a study 
of 900 elderly Catholic clergymen noted a linear trend between lower body mass and 
dementia risk with each one-unit decrease in BMI corresponding to a 5% increase in the 
risk of Alzheimer’s disease (12). Yet, studies of elderly adults provide an incomplete 
picture of the association between obesity and dementia across the lifespan. Body 
composition changes in old age and co-morbidities that lower body weight, such as 
respiratory disease and cancer, become increasingly common. Therefore single time-
point examination in the elderly may provide a poor estimate of lifetime exposure.  
Prospective epidemiological studies that have examined obesity and cognitive 
outcomes with a lifespan perspective, demonstrate that midlife obesity significantly 
increases the risk of dementia in old age. A study of community-dwelling middle-aged 
adults (ages 40-45 years) found that obese BMI was associated with a 3-fold increase in 
risk for Alzheimer’s disease and a 5-fold increase in risk for vascular dementia two 
decades later (13). Even with adjustment for diabetes and cardiovascular co-morbidities, 
this relationship remained intact. Similarly, the Cardiovascular Risk Factors, Aging, and 
Dementia (CAIDE) study found that midlife obesity was associated with a 2-fold 
increased risk for dementia. Co-morbid high cholesterol and high blood pressure had an 
additive effect with obesity, resulting in a 6-fold increased risk for dementia in old age 
(14).  
Even in the absence of dementia, midlife obesity has negative consequences on 




during middle-age was associated with poorer cognitive performance in the domains of 
memory and executive function in later life (15). Other studies have demonstrated that 
higher BMI at midlife is associated with sharper cognitive decline across the lifespan 
(6,16).  
Overall, the literature indicates that obesity has a non-linear relationship with 
cognitive outcomes across the lifespan. In the elderly, higher BMI decreases the risk of 
dementia (10,11), whereas in younger populations the opposite relationship has been 
found (14,13). In particular, obese midlife BMI appears to significantly increase the 
likelihood of dementia and cognitive deficits in old age (6,13-16).   
1.3 BMI and Brain Structure 
Obesity’s impact on cerebral health has been validated by findings of structural 
brain alterations in human and animal studies. Rats with diet-induced obesity demonstrate 
reduced hippocampal dendritic spine density (17) and have lower concentrations of 
synaptic marker proteins such as synapsin and GAP-43 (18). Similarly, in humans, 
obesity has been associated with hippocampal abnormalities. Greater visceral adiposity, 
as measured by waist-to-hip ratios, has been correlated with smaller hippocampal size 
independent of other cardiovascular risk factors (19). A longitudinal study found that 
obese BMI predicted smaller hippocampal volume 18-years later (20). Given the critical 
role of the hippocampus in learning and memory (21), these obesity-related structural 
alternations may translate into poorer cognitive performance.  Evidence for this 
hypothesis has been provided by animal models, which have demonstrated that obesity is 




synapses (17). In humans, reduced hippocampal volume is an independent risk factor for 
dementia (22).  
Obesity has also been associated with reduced whole brain volume independent of 
age and other cardiovascular risk factors (23,24). In particular, grey matter reductions 
have been observed in the orbitofrontal cortex, medial frontal lobes, inferior parietal 
cortex, lateral occipitipal lobe, cerebellum, and parahippocampus (25). Alterations in 
white matter have also been demonstrated in obesity. In comparison to wild-type mice, 
genetically obese ob/ob mice have significantly lower myelin concentrations and 
alterations in the fatty composition of myelin (26). In humans, obese BMI is associated 
with larger white matter volumes throughout the frontal, parietal, and occipital lobes (25) 
with some evidence of reversal with weight loss (27). Overall, the results from these 
studies suggest that obesity is associated with reduced whole brain and grey matter 
volumes and increased white matter volumes. Many of the regions displaying structural 
abnormalities are critical to higher cognitive processes such as attention, planning, and 
mental manipulation of information (28). Therefore, obesity-related atrophy may 
translate to poorer cognitive outcomes and increase vulnerability to cognitive decline. 
1.4 Proton Magnetic Resonance Spectroscopy (1H MRS) 
Proton magnetic resonance spectroscopy (1H MRS) is a non-invasive imaging 
technique that could potentially inform on the neurochemical alterations associated with 
obesity. 1H MRS capitalizes on the unique precession properties of atomic nuclei to 
measure concentrations of cerebral metabolites that reflect cellular structure, membrane 




neutrons, and electrons spin about their axis, creating a quantifiable angular momentum. 
Additionally, the mass and the positive charge of protons generate a small magnetic field 
referred to as the magnetic moment. The ratio between the angular and magnetic 
moments yields a gyromagnetic ratio unique to a particular nucleus. When placed in a 
magnetic field, the protons will precess at the frequency governed by the Larmor 
Equation; the strength of the magnetic field multiplied by the gyromagnetic ratio. A 
precise radio frequency pulse can then be generated to excite the nuclei. The difference 
between frequency of the emitted signal and the frequency of a reference signal divided 
by the reference signal yields the chemical shift, expressed in parts per million. The 
chemical shift is composed of a spread of peaks, each corresponding to different 
chemicals. The chemicals can be identified by their positions along the frequency axis 
due to their unique precession frequencies and their concentrations can be derived from 
the area under their peaks on the chemical shift (29).  
When 1H MRS is applied to the brain, several chemicals of neurobiological 
importance can be identified:  
• N-aceytl-aspartate (NAA) is expressed exclusively by neurons and 
oligiodendrocyte-type-2 astrocyte progenitor cells (30) and is regarded as 
a marker of neuronal viability (29). Reductions in NAA occur in disease 
states that result in neuronal loss such as Alzheimer’s disease (31), 
Parkinson’s disease (32), and stroke (33). NAA declines that correspond 
with injury severity and treatment outcomes have been observed after 




• Choline-containing compounds (free choline, phosphocholine and 
glycerophosphocholine, Cho), are mainly derived from soluble membrane 
phospholipids (35). Elevations in Cho concentrations are believed to 
reflect increased membrane breakdown, myelination, and inflammation 
(35). Increases in Cho have been observed in patients with malignant 
tumors (36), multiple sclerosis (31), and HIV infection (37).  
• Creatine and phosphocreatine form the CR peak. Due to their role in 
producing adenosine triphosphate (ATP) from adenosine diphosphate 
(ADP), their concentrations are thought to reflect energy use (38). Cr 
concentrations have generally been found stable across the lifespan except 
in conditions of altered cerebral metabolism such as brain tumors (39). For 
this reasons, Cr is often used as an internal reference for the quantification 
of other cerebral metabolite concentrations (29).  
• Myo-inositol (mI) is a simple sugar alcohol, which acts as an organic 
osmolyte and is a precursor for the second messanger inositol tri-phospate 
(40). Robust increases in mI have been observed in states of chronic 
hypernatremia (41).  Elevations in mI have also been reported in 
conditions associated with cognitive impairment such as Down’s 
syndrome (42) and Alzheimer’s disease (43).  
• Glutamate (Glu) is the most abundant excitatory neurotransmitter in the 
brain (44). Large increases in Glu have been found in states of enhanced 




1H MRS has revealed neurometabolite alterations in numerous disorders that 
correspond to the degree of cognitive impairment and future cognitive outcomes (34,43) 
Neurometabolite concentrations have also been shown to correlate with cognitive 
performance in healthy adults (47), implicating their relevance to general cognition. 
Moreover, 1H MRS has the capability to detect neurochemical alterations in brain tissue 
prior to the development of inflammatory (31) and cerebrovascular lesions (48), 
suggesting that it may have greater sensitivity than conventional MRI. Given these 
parameters, 1H MRS may be particularly adept at identifying subtle cerebral alterations in 
obese middle-aged adults that are otherwise healthy.  
1.5 General Summary 
 Midlife obesity is an important risk factor for dementia, cognitive decline, and 
cerebral atrophy in old age (20,4). Given that almost two out of three adults in the United 
States are classified as either overweight or obese (2) and the progressive aging of the US 
population, the link between obesity and dementia can easily translate into dire public 
health consequences. It is therefore crucial to understand the extent to which obesity 
affects the brain as well as the underlying mechanisms so that measures to prevent 
cognitive decline can be implemented. Current progress on these preventive efforts has 
been limited by the low sensitivity of traditional paper-and-pen cognitive tests. Ideally, 
the impact of obesity on cognition should be assessed before significant irreversible 
cognitive loss and cerebral atrophy has occurred. In this regard, 1H-MRS may be an ideal 
methodology because it provides an in vivo assessment of cerebral metabolite 




current study was to explore the association between BMI and markers of neuronal 




2. SUMMARY OF SPECIFIC AIM 
In elderly adults, high BMI has been identified a protective factor against 
dementia (9). However, epidemiological studies with longer follow-up periods have 
found that high BMI at midlife increases the risk of cognitive impairment (4,14) and 
correlates with the degree of cerebral atrophy in old age (19,20). The current study 
proposes to provide a real-time assessment of the association between midlife BMI and 
concentrations of cerebral metabolites with neurobiological significance using 1H MRS. 
Concentrations of five metabolites (NAA,Cho, Cr, mI, and Glu) were analyzed within the 
occipitoparietal grey matter. The region was selected because neurometabolite changes 
that correlate with the degree of cognitive impairment have been reliability detected in 
populations with cognitive disorders (43). It was hypothesized that higher BMI, as a risk 
factor of cognitive decline and structural brain alterations, would be associated with 
lower concentrations of NAA and higher concentrations of mI. NAA is a marker of 
neuronal viability (29) and lower levels have been identified in cognitive disorders with 
neuronal loss (32,34,43) and in healthy adults with poorer cognitive performance (47). mI 
is an organic osmolyte (50) which demonstrates elevations during the premorbid stages of 
cognitive disorders (43). NAA and mI were predicted to correlate with higher BMI due 




3. MATERIALS AND METHODS  
3.1 Participants 
 Right-handed adults between the ages of 40 and 60 years were recruited through 
flyers and newspaper advertisements. Individuals with a history of coronary artery 
disease, angina pectoris, myocardial infarctions, heart failure, and cardiac surgery were 
excluded. Additional exclusion criteria included history of neurological disease (e.g., 
stroke, Parkinson’s disease, clinically significant traumatic brain injury), major 
psychiatric illness (e.g. schizophrenia, bipolar disorder), substance abuse (i.e., diagnosed 
abuse and/or previous hospitalization for substance abuse), smoking (within the last two 
years), and MRI contraindications. Fifty-five participants completed the initial screen and 
were enrolled in the study after providing written consent. Two participants were 
excluded from analyses were excluded from the analyses due to poor quality MRS data 
(Cramer-Rao Lower Bounds for NAA/Cr, mI/Cr, Cho/Cr or Glu/Cr >12). Participant 
characteristics by group are presented in Table 1. 
3.2 Procedures 
 The study was approved by the Institutional Review Board of the University of 
Texas at Austin and all volunteers provided written informed consent before enrollment.  
Participants were required to complete a medical history interview in which medical 
conditions and treatments were coded as either present or absent based on participants’ 
self-report. Participants then underwent a full neuropsychological evaluation, brain 




glucose assay.  Visits were conducted on separate days and participants completed the 
study within one month. 
3.2.1 Neuropsychological Assessment 
 All participants completed a two-hour assessment battery including standard 
clinical neuropsychological instruments with established reliability and validity (51). All 
tests were administered and scoring using standard administration and scoring 
criteria.The battery included the following tasks: 
• Mini Mental Status Exam (MMSE) (52): a 30-item test of general mental status 
including arithmetic, memory, and orientation. Scores below 24 indicate possible 
dementia.  
• Wechsler Abbreviated Scale of Intelligence (WASI) (53): a test of general 
intelligence. The two subtest format consists of Vocabulary and Matrix 
Reasoning. Vocabulary is a measure of word knowledge with a maximum of 80 
possible points. Matrix Reasoning is a measure on non-verbal reasoning by 
analogy and has maximum of 35 (12-44 years) or 32 (45-79 years) total points.  
The two subtests can be used to calculate a full-scale IQ composite score with a 
mean of 100 and a standard deviation of 15.  
• Category Fluency for Animals (54): a measure of semantic fluency. Participants 
must name as many animals as they can in 1-minute.  
• Rey Complex Figure Test (RCF)(55): a measure of visiospatial constructional 
ability and visiospatial memory. Participants must copy a complex figure, which 




a 45-minute delay. Following the delay, participants also complete a recognition 
test.  The copy and free recalls are scored by giving credit to figure components 
that are correctly drawn and accurately place with a maximum of 36 total points. 
Partial credit is awarded for items that are incorrectly drawn but recognizable. For 
the recognition subtest, 1-point is awarded to each component that is correctly 
identified as being included or not included in the original figure with a maximum 
of 24 total points.   
• California Verbal Learning Test-II (CVLT-II) (56): a measure of verbal learning 
and memory. A 16-item word list is presented five times and participants must 
recall as many words as they can after each presentation. Following the 
presentation of a 16-word distracter list, participants are asked to recall the 
original list with and without semantic cuing. After a 20-mintute delay, 
participants recall the original list with and without semantic cuing and complete 
a yes/no item recognition test. Free recall trials have a maximum of 16 points with 
1-point awarded for each correctly recalled item from the list. A recognition 
discriminability index (d’) is calculated from the yes/no item recognition section. 
The calculation of d’ is based on the number of hits, number of possible total hits, 
number of false-positives, and number of total possible false-possible, yielding a 
maximum score of 4.0. 
• Wechsler Adult Intelligence Scale-III (WAIS-III) Digit Span Subtest (57): a 
measure of apprehension span and working memory. On Digits Forward, 




Backwards, participants must recall the numbers in reverse sequence. 1-point is 
awarded for each correctly sequenced item on Digits Forward and Backwards 
with their composite sums creating a Digits Total Score. 
• Controlled Oral Word Association Test (COWAT) (58): a measure of verbal 
fluency. Participants must name as many words as they can beginning with a 
specified letter within a 1-minute time frame. 
• Grooved Peg Board, Dominant hand (59): a measure of fine motor coordination. 
Participants must rotate key-shaped pegs to fill the 25 holes on the board as 
quickly as possible. Time to completion is recorded for both the dominant and 
non-dominant hands.    
• Trail Making Test A & B (60): a measure of visual attention and processing 
speed. For part A, participants draw a line connecting 25 randomly dispersed 
numbers in numerical order. On part B, participants must alternate between 
connecting randomly dispersed numbers and letters in sequence (1-A-2-B-3-C). 
Time to completion is recorded for both parts.  
• Beck Depression Inventory-II (BDI-II) (61): a 21-item self-report questionnaire 
assessing depression. The maximum scores is 63, with scores greater than 14 
suggesting clinically significant depression symptoms 
• Spielberger Trait Anxiety Inventory (STAI-T) (62): a 20-item self-report 
questionnaire on trait anxiety with higher scores representing greater anxiety.  




MRS data for each participant were acquired in a single session on a 3T GE Signa 
Excite MRI scanner equipped with a standard head coil.  Imaging included single voxel 
proton MRS performed using the GE pulse sequence PROBE-P, an automated point 
resolved spectroscopy (PRESS) sequence with chemical shift selected (CHESS) water 
suppression. Each spectroscopic voxel was prescribed from 3D high-resolution Spoiled 
Gradient Echo (SPGR) sagittal images (256 x 256 matrix, FOV = 24 x 24 cm2, 1 mm 
slice thickness, 0 gap) of the entire brain.  1H-MRS parameters were as follows: echo 
time/ repetition time (TE/TR) = 35/3000 ms, 128 excitations, 5000 Hz spectral width, 
volume ~6 cm3 from the occipitoparietal gray matter including posterior cingulate gyrus 
(Fig. 1). Neurometabolite concentrations in this region have consistently been found to 
correlate with cognitive function (34,43). Commercially available software, LCModel, 
was used to quantify and separate the metabolite resonances from the macromolecule 
background (63) (Fig. 2). In line with standard clinical protocols, the concentrations of 
NAA, Cho, mI, and Glu were reported as ratios relative to creatine (Cr) (43). 
3.2.3 General Health Assessment 
 Participants abstained from caffeine and fasted for at least four hours prior to the 
assessment. Body weight in kilograms and height in centimeters were measured on a 
beam-balance scale for the subsequent calculations of BMI. BMI was calculated by 
dividing weight in kilograms by height in meters squared. Following 15 minutes of rest, 
participants sat upright while brachial blood pressure was measured using a semi-




antecubital vein by venipucture. The concentrations of glucose, triglycerides, LDL-
cholesterol, and HDL-cholesterol were measured using standard enzymatic technique. 
3.3 Statistical Analyses 
 Neuropsychological measures were grouped into one of five cognitive domains:  
1) global cognitive functioning, 2) language functions, 3) visual-spatial abilities, 4) 
memory functions, and 5) attention-executive functions.  The following test scores were 
included in each domain and raw total scores were utilized unless otherwise stated:  1) 
global: MMSE (52) and WASI Full Scale IQ (53); 2) language: WASI Vocabulary 
Subtest (53) and Category Fluency for Animals (54); 3) visual-spatial: RCF copy (55) 
and WASI Matrix Reasoning Subtest (53); 4) memory: CVLT-II immediate recall, 
delayed recall, and recognition discrimination (56), RCF immediate recall, delayed recall, 
and recognition discrimination (55); 5) attention-executive- functions: Trail making A 
and B time to completion (60), COWAT (58), WAIS-III Digit Span Subtest (57), and 
Grooved Pegboard-Dominant Hand time to completion (59). Participants’ raw test scores 
were converted to z-scores using the study sample mean and standard deviation.  Timed 
test scores were multiplied by -1 so that higher scores indicate better performance.  Five 
composite cognitive domain z-scores were calculated for each participant by averaging 
the z-scores of all tests within that domain.  
 Descriptive statistics were calculated for demographics, medical variables, and 
raw cognitive test scores. Cognitive domain score scores were assessed in relation to BMI 
and 1H MRS markers  (NAA/Cr, Glu/Cr, mI/Cr and Cho/Cr) using linear regression 




MRS markers was analyzed using a single multivariate multiple linear regression model 
with all MRS parameters entered in at once, controlling for age, sex, fasting glucose 
levels, and systolic blood pressure. The above analysis was repeated using global 
cognition, anti-hypertensive medications, and hypoglycemic medications as additional 
covariates. All statistical analyses were performed using SPSS 16.0 (SPSS Inc., Chicago, 





4.1 Descriptive Statistics 
 Means and standard deviations of the demographic and medical variables of the 
sample are reported in Table 1. Table 2 displays the mean raw cognitive test scores and 
their standard deviations.  Descriptive statistical analyses revealed a cognitively normal, 
ethnically diverse, middle-aged sample, well representative of the population of the state 
of Texas based on year 2000 US census data for the state. Mean BMI was 29.4 kg/m2 
with a range from 19.0 to 42.8 kg/m2. Using the World Health Organization’s BMI 
categorization, 16 participants (28.1%) had a normal BMI (18.5–24.9 kg/m2), 15 
participants (26.3%) had an overweight BMI (25.0–29.9 kg/m2), and twenty-six 
participants (45.6%) had an obese BMI (>30 kg/m2).  Eleven participants were currently 
being treated with anti-hypertensive medications, three with lipid lowering agents, four 
with hypoglycemics, three with biphosphonates, one with thyroid replacement therapy, 
and one with antidepressant medications. 
4.2 BMI in Relation to Cognitive Test Performance 
 BMI was not significantly associated with performance on measures of language 
(F(3,51)=5.090, p=0.004, ß=-0.131, p=0.309), visual-spatial abilities (F(3,51)=0.375, 
p=0.772, ß=-0.096, p=0.512), memory (F(3,51)=1.318, p=0.280, ß=0.064, p=0.651), or  
attention-executive functions (F(3,51)=0.586, p=0.627, ß=-0.150, p=0.297) independent 
of age and years of education. However, there was a trend towards higher BMI relating to 
lower global cognitive function (F(3,51)=3.776, p=0.016, ß=-0.287, p=0.052). 




Consistent with the literature on mild cognitive impairment (43), higher levels of 
mI/Cr were associated with lower performance in the memory domain independent of age 
and years of education (F(3,51)=2.077, p=0.040, ß=-0.290, p=0.030). No significant 
relationship was found between NAA/Cr, Glu/Cr, and Cho/Cr and any domain of 
cognitive functioning independent of age and years of education. 
4.4 Cerebral Metabolism in Relation to BMI 
The fully adjusted multivariate regression model successfully predicted the level 
of mI/Cr in occipitoparietal grey matter (F(5,47)=3.583, p=0.008), but not NAA/Cr 
(F(5,47)=1.273, p=0.291), Cho/Cr (F(5,47)=1.393, p=0.244) or Glu/Cr (F(5,47)=1.526, 
p=0.200). Higher body mass index was significantly associated with higher mI/Cr 
(ß=0.387, p=0.006), independent of age, sex, fasting glucose levels, and systolic blood 
pressure (Fig. 3). This relationship remained unchanged when global cognition function 
was included in the model (F(6,45)=3.099, p=0.013, ß=0.389, p=0.010). Additionally, 
controlling for the use of anti-hypertensive (F(6,45)=2.935, p=0.017, ß=0.376, p=0.012) 
or hypoglycemic medications (F(6,45)=2.889, p=0.018, ß=0.394, p=0.006) did not alter 





5.1 Summary of Findings 
 The main finding from the study was that higher BMI was associated with 
elevations of mI/Cr in the occipitoparietal grey matter independent of age, sex, systolic 
blood pressure, and fasting glucose levels. Elevations in mI were predicted based on 
similar findings in other cognitively vulnerable population (42,43). However, the 
predicted relationship between higher BMI and lower NAA was not observed. 
Reductions in NAA frequently co-occur with elevations in mI in cognitively vulnerable 
populations (43,64). However, reductions in NAA and elevations in mI do not necessarily 
correlate with one another (64), suggesting that they reflect different pathological 
processes. NAA is a marker of neuronal viability and reductions have typically been 
observed in disorders with cerebral atrophy (29). In contrast, mI is an organic osmolyte 
and proposed maker of gliosis (40). The findings suggest that osmotic regulation and/or 
glial cell alterations may precede the neuronal loss associated with higher BMI.   
5.2 Myo-inositol and Cognition 
Elevations in mI/Cr have been noted in numerous populations with cognitive 
deficits such as those with mild cognitive impairment (65) and Alzheimer’s disease (43). 
In these populations, mI/Cr has demonstrated significant associations with the degree of 
cognitive decline (65,43). Elevations in mI/Cr have also been noted in adults with Down 
syndrome (42) and individuals at genetic risk for Alzheimer’s disease (66) before the 
onset of dementia, suggesting that alterations in mI/Cr emerge early in the pathogenic 




scores on the memory domain despite overall normal cognitive performance. These 
results suggest that individuals with higher BMI may be demonstrating alterations in 
neurochemistry associated with increased cognitive vulnerability. Further work will be 
necessary to determine the utility of these findings for future cognitive trajectories. 
5.3 Myo-inositol’s Role in the Central Nervous System   
Myo-inositol is a simple sugar alcohol with high cerebral concentrations (50). The 
neurometabolite can be produced de novo from glucose within the brain or it can be 
transported from the plasma (67). Due to its high concentrations within glial cells, myo-
inositol is a proposed marker of gliosis (43,68). Additionally, myo-inositol is an organic 
osmolyte and a precursor for membrane phospholipids and for the second messenger 
inositol tri-phosphate (50). High levels of myo-inositol have been reported in patients 
with diabetes (69-71) and hypertension (72), conditions closely related to obesity. In the 
current study, BMI was associated with elevations in mI/Cr even after controlling for 
systolic blood pressure, fasting glucose levels, anti-hypertensive medications, and 
hypoglycemic agents, suggesting that high BMI uniquely accounted for some of the 
variance in mI/Cr values in the occipitoparietal grey matter. 
5.4 Myo-inositol, Obesity, and Osmotic Regulation 
Myo-inositol’s role as organic osmolyte may explain its association with BMI. 
Neural and non-neural cells within the brain experience constant fluctuations in the 
concentrations of electrolytes transported across the plasma membrane. This must be 
closely regulated to prevent large alterations in the water diffusion, which could lead to 




concentrations are regulated by ions but during chronic conditions organic osmolytes 
resume this function (73). Chronic hypernatremia induces robust increases in myo-
inositol concentrations in the brain that is governed by sodium dependent myo-inositol 
cotransport (41,74,73). The upregulation of the sodium dependent myo-inositol 
cotransport and subsequent increase in brain myo-inostiol is extremely sensitive to 
osmotic stress, so even small, persistent changes in plasma tonicity may increase myo-
inositol concentrations in the brain (73). 
Interestingly, overweight and obese individuals have higher extracellular relative 
to intracellular body fluid (ECF/ICF) that is presumed to be due to higher plasma tonicity 
(75). Glucose dysregulation is a well-documented cause and consequence of both obesity 
(76) and plasma hypertonicity (77). A prior study found that obese individuals were 50% 
more likely to have plasma hypertonicity than lean controls even after controlling for 
plasma glucose (75). Plasma hypertonicity in the obese individuals was strongly 
associated with higher plasma sodium concentrations in addition to elevated glucose 
levels. Evidence also suggests that obese individuals may have altered ECF/ICF in the 
brain. Diffusion weighted imaging demonstrated that obese individuals have higher 
apparent diffusion coefficient (ADC) values in numerous regions throughout the brain in 
comparison to lean controls (78). ADC values represent the diffusion of water molecules 
within a tissue and vasogenic edema, a condition associated with an increase in 
extracellular water distribution, is related to higher ADC values (79). Similarly in obese 
individuals, higher ADC values may represent an increased ECF secondary to plasma 




upregulated to maintain osmotic balance.  Thus, plasma hypertonicity may be a 
mechanism linking higher BMI to elevations in cerebral myo-inositol.  
5.5 Myo-inositol, Obesity, and Inflammation 
Another condition that may explain the association between myo-inositol and 
BMI is gliosis subsequent to inflammation. Insult or injury in the brain induces astrocyte 
proliferation and the presence of activated microglia, which release inflammatory 
cytokines and oxidative radicals (80). Myo-inositol resides primarily in glial cells so 
inflammatory-induced gliosis may increase its cerebral concentrations (43,68). 
Accordingly, elevations in myo-inositol have been detected in several conditions 
associated with neuroinflammation such as multiple sclerosis (31), acquired 
immunodeficiency syndrome (81), and Alzheimer’s disease (43).  
 Inflammation is also a well-established symptom of obesity. Adipose tissue 
secretes numerous cytokines, some which are capable of crossing the blood brain barrier 
and initiating a local proinflammatory response (82). In rodents, high fat diets have been 
shown to increase astrocyte proliferation, activated microglia, and brain levels of 
proinflammatory cytokines (83). Furthermore, leptin, a hormone secreted in proportion to 
adipose tissue, can cross the blood brain barrier and alter inflammatory signaling in 
microglia (84). Obesity-related inflammation may therefore be a potential mechanism 
responsible for elevated myo-inositol concentrations. 
5.6 Comparison with Previous Findings  
The current study found a strong association between myo-inositol and BMI. 




for myo-inositol levels (85,86). Examining middle-aged adults, Gadzinksi et al. (2008) 
(85) reported that greater BMI was associated with lower NAA/Cr levels in the frontal, 
parietal, and temporal white matter, lower NAA/Cr in the frontal grey matter, and lower 
Cho/Cr in the frontal white mater. In a similar study of older adults, Gazdzinski et al. 
(2010) (86) found that BMI was related with decreased NAA/Cr and Glu/Cr in the 
anterior cingulate. The differences in findings may be due to regional tissue variation in 
neurometabolite concentrations. The current study examined a voxel within the 
occipitoparietal lobe. When the prior studies examined posterior brain regions, they also 
found no association between NAA/Cr and BMI. Nonetheless, elevations in mI/Cr 
concentrations are a unique finding in the current study. This discrepancy could be 
explained methodological variance. The study conducted by Gazdzinski et al. (2008) (85) 
acquired data from a 1.5-Telsa scanner with an echo time/ repetition time (TE/TR) = 
25/1800 ms. In Gazdzinski et al. (2010) (86) a 4-Telsa scanner with a TE/TR = 15/2000 
was utilized. The current study was conducted on a 3-Telsa scanner with a TE/TR = 
35/3000 ms. Differences in magnetic field strength and TE/TR parameters can alter 
quantifiable precision due to changes in the signal-to-noise ratio and chemical shift 
dispersion (87). The variation in findings between the current study and previous ones 
may also be explained by differences in the participant sample. In the current study, a 
relatively large proportion of participants were obese (45.6%) in comparison to the sparse 
representation of obesity in the other two studies, 10% (85) and 0% (86) respectively. It 





5.7 Study Limitations  
While contemplating the results of the study, it is important to consider its 
strengths and limitations. The primary strength of the current study was its detailed 
characterization of the study participants in terms of medical history and cognitive 
function. All participants underwent a structured medical history interview to help avoid 
a potential under-reporting bias in response to self-report forms. The detailed cognitive 
assessment provided a thorough assessment of participants’ cognitive functioning across 
multiple domains including global cognitive functioning, language functions, visual-
spatial abilities, memory, and attention-executive-psychomotor functions. The study also 
included objective assessment of physiological indices such as fasting glucose levels and 
systolic blood pressure. This enabled us to control for common co-morbidities associated 
with obesity and cerebral alterations in order to determine BMI’s independent impact on 
cerebral neurochemistry. A limitation of the study was that the overall sample size was 
relatively small, so the present findings must be considered preliminary. Also, the 
occipitoparietal region that was sampled contains mostly grey matter but does inherently 
include some white matter. Neurometabolite concentrations have been noted to vary 
between grey and white matter tissue (35). Changes in grey/white matter composition 
have been reported in association with BMI (25), so tissue segmentation may be a useful 
correction. The current study performed spectroscopy on a single region of interest. 
Inclusion of multiple voxels would provide better characterization of BMI-related 
alterations across the cerebral cortex. Finally, the cross-sectional nature of the study is a 




a result of higher BMI. It is also unclear as to whether mI elevations would reverse with 
successful weight loss. Most importantly, longitudinal studies will be critical in 
determining whether the observed alterations in neurochemical concentrations are 
predictive of individual cognitive trajectories. 
5.8 Summary  
In conclusion, the main finding of the current study was that higher BMI was 
associated with elevations in mI/Cr concentrations in the occipitoparietal grey matter 
independent of age, sex, systolic blood pressure, and fasting glucose levels. This finding 
adds to the accumulating literature demonstrating that obesity has an adverse impact on 
central nervous system functioning. Several studies have indicated that obesity is a risk 
factor for dementia and cognitive decline and relates to structural alterations in brain 
volume. The current study provides evidence that higher midlife BMI is related to 
increased cerebral mI/Cr ratio, potentially implicating plasma hypertonicity and 
neuroinflammation as mechanisms underlying obesity-related brain dysfunction. 
Longitudinal studies will be necessary to determine if the observed neurometabolic 
alterations are predictive of cognitive vulnerability. With validation and absolute 
quantification, studies of neurometabolites may help uncover the pathological 




APPENDIX A. TABLES 
Table 1. Participant Characteristics  
 Mean+SD 
Age, y 50.8±6.6 
Sex (male/female), n 25:28 
Race, n (%) 
           Caucasian 
           Hispanic 
           African American 






Education, y 15.2±2.9 
Body mass index, kg/m2 29.6±5.9 
Systolic blood pressure, mmHg 124.9±15.7 
Diastolic blood pressure, mmHg 75.4±8.8 
LDL-Cholesterol, mg/dl 124.3±34.0 
HDL-Cholesterol, mg/dl 48.4±16.7 
Triglyceride, mg/dl 166.8±97.4 








Table 2. Neuropsychological Test Results 
Cognitive Domain Mean+SD 
Global cognition  
 Mini Mental Status Exam (MMSE) 
Weschler Abbreviated Test of Intelligence (WASI)  





WASI - Vocabulary Subtest 





WASI Matrix Reasoning Subtest 




Memory   
California Verbal Learning Test (CVLT) 
       Immediate Recall 
       Delayed Recall 
       Recognition (Yes/No) 










      Immediate Recall 
      Delayed Recall 




Attention-executive function  
Controlled Oral Word Association Test (COWAT) 
Trail Making Test A, sec 
Trail Making Test B, sec 
Weschler Adult Intelligence Scale III (WAIS-III) 
Digit Span Subtest, total 









Beck Depression Inventory II (BDI-II) 










APPENDIX B. FIGURES 
Figure 1. MRS Voxel Borders on High Resolution Anatomy Indicating Volume of 







Figure 2. Representative 1H MRS Spectrum 
 The narrow line width and small residual indicate excellent model fit.  NAA = N-acetyl-
aspartate; Glu = glutamate; Cr = creatine + phosphocreatine; Cho = choline + 
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